Health - Greatreporter

ProMIS Neurosciences Presents at 2022 Alzheimer’s Association International Conference

August 2, 2022 R Powell

ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, today announced details of its poster presentation at the annual Alzheimer’s Association International Conference (AAIC®) being held from July 31-August 4, 2022 […]

ProMIS Neurosciences to Present at 2022 Alzheimer’s Association International Conference

July 27, 2022 R Powell

ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the development of neurodegenerative diseases, today announced it will give a poster presentation at the annual Alzheimer’s Association International Conference (AAIC®) to be held July 31-August 4, […]

ProMIS Neurosciences Announces Filing of Form 10 Registration Statement and Nasdaq Listing Application

June 22, 2022 R Powell

ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the development of neurodegenerative diseases, today announced that it has filed a registration statement on Form 10 (the “Registration Statement”) with the United […]

ProMIS Neurosciences Announces Debt Amendment and Conversion

June 22, 2022 R Powell

ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the development of neurodegenerative diseases, is pleased to announce that it has entered into debenture amendments with seven (7) creditors to settle an […]

ProMIS Neurosciences Announces Authorization of Series 1 Preferred Shares

June 22, 2022 R Powell

ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the development of neurodegenerative diseases, today announced that it has amended its articles to authorize the issuance of 70,000,000 Series 1 Preferred Shares […]

Kosmik Brands Launches in Planet 13

May 24, 2022 R Powell

Soon after Kosmik Brands launched in the great state of Nevada, they are back with more exciting news. Planet 13, globally recognized as the largest cannabis dispensary in the world, now carries all Kosmik products. Setting the world record with their opening back in 2018, since day one, Planet 13 continues to set the bar […]

TOP GUN: MAVERICK STAR BUILT IMPRESSIVE PHYSIQUE IN SEVEN WEEKS WITH ULTIMATE PERFORMANCE

May 23, 2022 R Powell

Glen Powell plays ‘Hangman’ in the long-awaited sequel, starring alongside Hollywood legend Tom Cruise. Shooting for the film began in 2018, and Glen had just seven weeks to get into incredible shape for a sequence in which he is seen shirtless playing American Football– a homage to the iconic volleyball scene in the original […]

4Ever Young Anti Aging Solutions Takes the Lead in the Race for Age Sustainability

May 17, 2022 R Powell

Move over medspas… 4Ever Young breaks the mold with ultramodern services designed to turn back the clock. 4Ever Young Anti Aging Solutions hosted a ribbon-cutting ceremony in Parkland, adding a third corporate location to a heavy-hitting portfolio that includes locations in Ft. Lauderdale and Boca Raton. The brand, who began expansion in 2017, has 8 […]

ProMIS Neurosciences Reports New Milestones in Potential Therapeutic Approaches for Amyotrophic Lateral Sclerosis (ALS)

April 28, 2022April 30, 2022 ciaran

ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of potential therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today new milestones in potential therapeutic approaches for ALS. Almost all cases of ALS, and about half of cases of […]

ProMIS appoints experienced industry veteran Larry Altstiel as Chief Medical Officer

April 19, 2022April 30, 2022 ciaran

ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today that it has appointed Larry Altstiel M.D. Ph.D., as Chief Medical Officer. Brings decades of experience in Alzheimer’s research […]